UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 119

Sortiert nach

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

The New England journal of medicine, 2017-07, Vol.377 (3), p.222-232

2017

Link zum Volltext

Verfügbarkeit prüfen

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

The Lancet (British edition), 2016-11, Vol.388 (10057), p.2239-2253

2016

Link zum Volltext

Verfügbarkeit prüfen

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Nature biotechnology, 2019-06, Vol.37 (6), p.640-650

2019

Link zum Volltext

Verfügbarkeit prüfen

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

Journal of lipid research, 2016-03, Vol.57 (3), p.340-351

2016

Link zum Volltext

Verfügbarkeit prüfen

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

The Lancet (British edition), 2015-10, Vol.386 (10002), p.1472-1483

2015

Link zum Volltext

Verfügbarkeit prüfen

Targeting APOC3 in the Familial Chylomicronemia Syndrome

The New England journal of medicine, 2014-12, Vol.371 (23), p.2200-2206

2014

Link zum Volltext

Verfügbarkeit prüfen

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Circulation research, 2013-05, Vol.112 (11), p.1479-1490

2013

Link zum Volltext

Verfügbarkeit prüfen

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

Nature communications, 2015-04, Vol.6 (1), p.6498-6498, Article 6498

2015

Link zum Volltext

Verfügbarkeit prüfen

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

The Journal of clinical investigation, 2016-08, Vol.126 (8), p.2855-2866

2016

Link zum Volltext

Verfügbarkeit prüfen

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Diabetes care, 2016-08, Vol.39 (8), p.1408-1415

2016

Link zum Volltext

Verfügbarkeit prüfen

Antisense technology: an overview and prospectus

Nature reviews. Drug discovery, 2021-06, Vol.20 (6), p.427-453

2021

Link zum Volltext

Verfügbarkeit prüfen

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

Journal of lipid research, 2007-04, Vol.48 (4), p.763-767

2007

Link zum Volltext

Verfügbarkeit prüfen

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9

Arteriosclerosis, thrombosis, and vascular biology, 2015-07, Vol.35 (7), p.1589

2015

Link zum Volltext

Verfügbarkeit prüfen

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice

Journal of lipid research, 2021-01, Vol.62, p.100101-100101, Article 100101

2021

Link zum Volltext

Verfügbarkeit prüfen

Antisense technology: A review

The Journal of biological chemistry, 2021-01, Vol.296, p.100416-100416, Article 100416

2021

Link zum Volltext

Verfügbarkeit prüfen

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes

Proceedings of the National Academy of Sciences - PNAS, 2015-05, Vol.112 (20), p.E2611-E2619

2015

Link zum Volltext

Verfügbarkeit prüfen

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B

Circulation (New York, N.Y.), 2006-10, Vol.114 (16), p.1729-1735

2006

Link zum Volltext

Verfügbarkeit prüfen

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

Journal of the American College of Cardiology, 2011-04, Vol.57 (15), p.1611-1621

2011

Link zum Volltext

Verfügbarkeit prüfen

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

Circulation (New York, N.Y.), 2008-08, Vol.118 (7), p.743-753

2008

Link zum Volltext

Verfügbarkeit prüfen

Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation

Cell reports (Cambridge), 2016-07, Vol.16 (4), p.939-949

2016

Link zum Volltext

Verfügbarkeit prüfen

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies

Bioscience reports, 2019-01, Vol.39 (1)

2019

Link zum Volltext

Verfügbarkeit prüfen

Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice

American journal of physiology. Regulatory, integrative and comparative physiology, 2012-04, Vol.302 (8), p.R996-R1003

2012

Link zum Volltext

Verfügbarkeit prüfen

The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis

Journal of lipid research, 2017-02, Vol.58 (2), p.420-432

2017

Link zum Volltext

Verfügbarkeit prüfen

Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1

PLoS genetics, 2018-10, Vol.14 (10), p.e1007732-e1007732

2018

Link zum Volltext

Verfügbarkeit prüfen

Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion

PloS one, 2014-06, Vol.9 (6), p.e98953-e98953

2014

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 119

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(115)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(118)
Buchkapitel
(1)

Sprache

Englisch
(119)
Japanisch
(33)

Erscheinungsjahr

n.n

Thema

Science & Technology
(92)
Life Sciences & Biomedicine
(86)
Animals
(72)
Mice
(53)
Humans
(36)
Male
(35)
Liver - Metabolism
(33)
Biochemistry & Molecular Biology
(26)
Oligonucleotides, Antisense - Pharmacology
(25)
Female
(23)
Mice, Inbred C57bl
(22)
Mice, Knockout
(20)
Antisense Oligonucleotides
(19)
Biological And Medical Sciences
(19)
Medical Sciences
(18)
Pharmacology & Pharmacy
(16)
Apolipoproteins
(15)
Atherosclerosis
(15)
Cell Biology
(15)
Cardiovascular System & Cardiology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Targeting APOC3 in the Familial Chylomicronemia Syndrome

Antisense Oligonucleotide Inhibition of Apolipoprotein C-III Reduces Plasma Triglycerides in Rodents, Nonhuman Primates, and Humans

Flavin-containing monooxygenase 3 as a potential player in diabetes-associated atherosclerosis

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

Antisense-Mediated Lowering of Plasma Apolipoprotein C-III by Volanesorsen Improves Dyslipidemia and Insulin Sensitivity in Type 2 Diabetes

Antisense technology: an overview and prospectus

Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice

Role of Insulin in the Regulation of Proprotein Convertase Subtilisin/Kexin Type 9

Antisense oligonucleotide–mediated inhibition of angiopoietin-like protein 3 increases reverse cholesterol transport in mice

Antisense technology: A review

Apolipoprotein CIII links islet insulin resistance to β-cell failure in diabetes

Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

Regulation of Hepatic Triacylglycerol Metabolism by CGI-58 Does Not Require ATGL Co-activation

Antisense oligonucleotides targeting angiotensinogen: insights from animal studies

Reduction of TIP47 improves hepatic steatosis and glucose homeostasis in mice

The lipid droplet-associated protein perilipin 3 facilitates hepatitis C virus-driven hepatic steatosis

Mouse genome-wide association studies and systems genetics uncover the genetic architecture associated with hepatic pharmacokinetic and pharmacodynamic properties of a constrained ethyl antisense oligonucleotide targeting Malat1

Acute sterol o-acyltransferase 2 (SOAT2) knockdown rapidly mobilizes hepatic cholesterol for fecal excretion

Suchergebnisse filtern